首页/数据集/Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer

Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer

NIAID Data Ecosystem2026-05-01 收录

结直肠癌靶向治疗

BRAF突变联合用药

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/67803 数据链接链接失效反馈

官方服务：

资源简介：

To explore the efficacy and safety of Cetuximab in combination with dabrafenib and Tislelizumab in BRAF mutated treatment of advanced colorectal cancer

应用场景：

创建时间：

2023-08-15

结直肠癌靶向治疗

肿瘤免疫联合疗法

Data from a prior phase II study of single agent cabozantinib in metastatic, refractory colorectal cancer (NCT03542877) combined with the compelling preclinical data in colorectal mouse models utilizi

NIAID Data Ecosystem70

Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer

结直肠癌靶向治疗

II期临床试验

RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of recurrent metastatic colorectal cancer. PURPOSE: Randomized phase II trial to

NIAID Data Ecosystem30

Table_1_The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis.docx

结直肠癌靶向治疗

临床荟萃分析

BackgroundPatients with locally advanced rectal cancer (LARC) are at higher risk of local and distant recurrence and are thus more vulnerable to metastatic diseases. Neoadjuvant chemoradiotherapy (nCR

NIAID Data Ecosystem10

Supplementary Material for: Safe Administration of Fruquintinib in a Hemodialysis Patient with Metastatic Colorectal Cancer: A Case Report

结直肠癌靶向治疗

血液透析患者用药安全

**Background:** Fruquintinib is a selective vascular endothelial growth factor receptor (VEGFR) inhibitor approved for metastatic colorectal cancer (mCRC) that is refractory to standard therapies. Whi

Figshare2025-12-02 更新50

Tretinoin synergistically enhances the antitumor effect of combined BRAF, MEK, and EGFR inhibition in BRAFV600E colorectal cancer [HT29 samples]

结直肠癌靶向治疗

药物协同作用

Patients with BRAF-mutated colorectal cancer (BRAFV600E CRC) are currently treated by a combination of BRAF inhibitor and anti-EGFR antibody with or without MEK inhibitor. A fundamental problem in tre

NIAID Data Ecosystem10

Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer

资源简介：

相关数据集